SYMBIOTEC PHARMALAB Q2 Results FY27: Net Profit Jumps 267.85% QoQ to Rs 51.72 Cr, Revenue Rs 279.93 Cr

SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Q2 Results FY27 announced on 5 November 2026, covering the company's financial performance for the July to September quarter. The company reported consolidated revenue of Rs 279.93 Cr and PAT of Rs 51.72 Cr, and the results date of 5 November 2026 anchors every comparison below. SYMBIOTEC PHARMALAB Q2 Results FY27 is measured against the previous quarter, on the consolidated results as filed.

This SYMBIOTEC PHARMALAB Q2 Results results analysis covers the financial highlights, the business drivers, the outlook and the risks, in that order. The results analysis begins with the Financial Highlights table, which sets each reported line beside its previous-quarter figure.

Click Here – Get Free Investment Predictions

SYMBIOTEC PHARMALAB Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q1 FY27 (Jun 26)	QoQ Change
Revenue	Rs 279.93 Cr	Rs 218.15 Cr	+28.32% QoQ
Operating Profit	Rs 91.51 Cr	Rs 45.2 Cr	+102.46% QoQ
Net Profit (PAT)	Rs 51.72 Cr	Rs 14.06 Cr	+267.85% QoQ

Source: company filing for SYMBIOTEC PHARMALAB Q2 Results FY27, 5 November 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from SYMBIOTEC PHARMALAB Q2 Results: What Stands Out

• Revenue: Consolidated revenue grew 28.32% QoQ to Rs 279.93 Cr from Rs 218.15 Cr, an addition of Rs 61.78 Cr over the previous quarter.
• Net profit: Net profit rose 267.85% QoQ to Rs 51.72 Cr from Rs 14.06 Cr, an addition of Rs 37.66 Cr over the previous quarter.
• Operating Profit: Operating Profit reached Rs 91.51 Cr against Rs 45.20 Cr in the previous quarter, a QoQ growth of 102.46% within SYMBIOTEC PHARMALAB Q2 Results FY27.
• Net profit margin: Net profit margin improved to 18.5% from 6.4% in the comparison quarter, as the disclosed figures show.
• Next step: The performance analysis below compares revenue growth of 28.32% with net profit growth of 267.85% in more detail.

SYMBIOTEC PHARMALAB Q2 Results FY27: Performance Analysis

SYMBIOTEC PHARMALAB grew consolidated revenue by 28.32% QoQ to Rs 279.93 Cr in the July to September 2026 quarter, and net profit rose 267.85% QoQ to Rs 51.72 Cr. Operating Profit increased 102.46% QoQ to Rs 91.51 Cr. This SYMBIOTEC PHARMALAB Q2 Results FY27 analysis shows every reported line above its previous-quarter level.

The quarterly results show profit lines growing faster than the top line. Revenue added Rs 61.78 Cr to the Rs 218.15 Cr of the previous quarter, Operating Profit added Rs 46.31 Cr to Rs 45.20 Cr, and net profit added Rs 37.66 Cr to Rs 14.06 Cr. In SYMBIOTEC PHARMALAB Q2 Results, each line therefore grew, at different QoQ rates.

Investors will focus on whether profit growth holds against revenue growth in later disclosures, and on how the consolidated results compare with the figures in SYMBIOTEC PHARMALAB Q2 Results FY27 when the next quarter is filed. Those numbers set the context for the drivers behind the quarter, which is where the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The results analysis points first to revenue, which grew 28.3% quarter on quarter to Rs 279.93 Cr in the latest quarter. This sets the scale of the quarter in SYMBIOTEC PHARMALAB Q2 Results FY27 and is the base for the profit lines.

Net Profit – Net profit rose 267.9% quarter on quarter to Rs 51.72 Cr, a far larger percentage gain than revenue. The quarterly results therefore show profit growing much faster than sales.

Net Profit Margin – Net profit margin improved to 18.5% from 6.4% in the comparison quarter. This margin figure follows from net profit of Rs 51.72 Cr on revenue of Rs 279.93 Cr in the July to September 2026 quarter.

FY27 Outlook After SYMBIOTEC PHARMALAB Q2 Results

FY27 full-year results will depend on the quarters still to be reported and on disclosed sector conditions. SYMBIOTEC PHARMALAB Q2 Results FY27 gives one reference point, with revenue at Rs 279.93 Cr and net profit at Rs 51.72 Cr for the second quarter, and the results analysis of later filings will show how these levels compare.

Readers can follow SYMBIOTEC through the Univest Screener and the Univest app as later filings arrive. Revenue and net profit will each be compared with the previous quarter in the next filing, so the pace of both lines is worth tracking, and the risks that follow set out what else to watch.

Key Risks to Watch After SYMBIOTEC PHARMALAB Q2 Results FY27

Lower Return on Equity

Return on equity declined to 11.22% in FY26 from 12.69% in FY25. This is a decline of 1.47 percentage points, and it sits alongside the growth reported in SYMBIOTEC PHARMALAB Q2 Results FY27, so later filings will show how the ratio moves.

Lower Return on Capital Employed

Return on capital employed declined to 12.41% in FY26 from 14.14% in FY25. This is a decline of 1.73 percentage points between the two financial years, and QoQ growth in later quarters will be read against it.

Return on Equity Below 15%

Return on equity of 11.22% in FY26 is below 15%. This is a threshold comparison on the FY26 figure, and later filings will show whether the ratio moves closer to or further from that level.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

SYMBIOTEC PHARMALAB Q2 Results FY27 show consolidated revenue of Rs 279.93 Cr and net profit of Rs 51.72 Cr for July to September 2026. These quarterly results record higher figures than the previous quarter on every reported line, and the consolidated results will be set against the next filing. SYMBIOTEC PHARMALAB Q2 Results also point readers to the return on equity and return on capital employed figures. Investors should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on SYMBIOTEC PHARMALAB Q2 Results FY27

What are SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. SYMBIOTEC PHARMALAB Q2 Results FY27 are the consolidated results for the second quarter, with revenue of Rs 279.93 Cr and net profit of Rs 51.72 Cr. Alongside this, each line is compared with the previous quarter.

What is the results date for SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. The results date for SYMBIOTEC PHARMALAB Q2 Results FY27 is 5 November 2026, covering July to September 2026. This means the consolidated figures were declared on that day, as the opening paragraphs of the article state.

What revenue was reported in SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. SYMBIOTEC PHARMALAB reported consolidated revenue of Rs 279.93 Cr, against Rs 218.15 Cr in the previous quarter, so the Financial Highlights table shows an increase of Rs 61.78 Cr over the comparison quarter.

What net profit was reported in SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. Net profit came in at Rs 51.72 Cr compared with Rs 14.06 Cr in the previous quarter, which means PAT moved up by Rs 37.66 Cr, as the Performance Analysis section explains.

How much QoQ growth did revenue show in SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. Revenue showed QoQ growth of 28.32% in SYMBIOTEC PHARMALAB's consolidated results, while Operating Profit grew 102.46% QoQ, so profit lines grew faster, as the Key Takeaways section shows.

Did net profit rise or fall in SYMBIOTEC PHARMALAB Q2 Results?

Ans. Net profit rose in SYMBIOTEC PHARMALAB Q2 Results, up 267.85% QoQ to Rs 51.72 Cr, while revenue rose slower at 28.32%, so the Performance Analysis section covers the gap between the two growth rates.

What was the Operating Profit in SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. Operating Profit in SYMBIOTEC PHARMALAB Q2 Results FY27 was Rs 91.51 Cr, compared with Rs 45.20 Cr in the previous quarter, which is a QoQ growth of 102.46% listed in the Financial Highlights table.

Are SYMBIOTEC PHARMALAB Q2 Results consolidated results or standalone results?

Ans. SYMBIOTEC PHARMALAB Q2 Results are consolidated results, so every figure describes the company with its subsidiaries together, which is why the Quick Answer and the Conclusion both state the consolidated basis.

What business factors shaped SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. The disclosed factors are revenue growth of 28.3%, net profit growth of 267.9% and a net profit margin of 18.5% against 6.4%, as the Key Business Factors section details.

What are the key risks after SYMBIOTEC PHARMALAB Q2 Results FY27?

Ans. The disclosed risks are return on equity falling to 11.22% from 12.69%, return on capital employed falling to 12.41% from 14.14%, and return on equity below 15%, per the Key Risks section.

What is the outlook after SYMBIOTEC PHARMALAB Q2 Results?

Ans. FY27 full-year results will depend on later quarters and disclosed sector conditions, so revenue of Rs 279.93 Cr and net profit of Rs 51.72 Cr are one reference point, as the Outlook section notes.

Where can I find the complete SYMBIOTEC PHARMALAB Q2 Results FY27 data?

Ans. The complete SYMBIOTEC PHARMALAB Q2 Results FY27 data sits in the Financial Highlights table above and on the Univest Screener, which means readers can compare every line with the previous quarter.